DK2802319T3 - Fastdosiskombinationsterapi for parkinsons sygdom - Google Patents
Fastdosiskombinationsterapi for parkinsons sygdomInfo
- Publication number
- DK2802319T3 DK2802319T3 DK13736198.6T DK13736198T DK2802319T3 DK 2802319 T3 DK2802319 T3 DK 2802319T3 DK 13736198 T DK13736198 T DK 13736198T DK 2802319 T3 DK2802319 T3 DK 2802319T3
- Authority
- DK
- Denmark
- Prior art keywords
- parkinson
- disease
- combination therapy
- dose
- fixed dosage
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 abstract 3
- 229960003089 pramipexole Drugs 0.000 abstract 3
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 abstract 3
- 229960000245 rasagiline Drugs 0.000 abstract 3
- 229940000425 combination drug Drugs 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261585824P | 2012-01-12 | 2012-01-12 | |
| PCT/IL2013/050025 WO2013105092A1 (en) | 2012-01-12 | 2013-01-10 | Fixed dose combination therapy of parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2802319T3 true DK2802319T3 (da) | 2018-01-29 |
Family
ID=48781101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13736198.6T DK2802319T3 (da) | 2012-01-12 | 2013-01-10 | Fastdosiskombinationsterapi for parkinsons sygdom |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20150079187A1 (https=) |
| EP (1) | EP2802319B1 (https=) |
| JP (1) | JP6243351B2 (https=) |
| KR (2) | KR102276896B1 (https=) |
| CN (1) | CN104168896B (https=) |
| AU (1) | AU2013208653B2 (https=) |
| CA (1) | CA2860952C (https=) |
| CY (1) | CY1119793T1 (https=) |
| DK (1) | DK2802319T3 (https=) |
| ES (1) | ES2655676T3 (https=) |
| HU (1) | HUE038029T2 (https=) |
| IL (1) | IL233572B (https=) |
| IN (1) | IN2014MN01568A (https=) |
| LT (1) | LT2802319T (https=) |
| MX (1) | MX360409B (https=) |
| NO (2) | NO2802319T3 (https=) |
| PL (1) | PL2802319T3 (https=) |
| PT (1) | PT2802319T (https=) |
| RS (1) | RS56742B1 (https=) |
| RU (1) | RU2642962C9 (https=) |
| WO (1) | WO2013105092A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5769923B2 (ja) | 2006-04-03 | 2015-08-26 | テバ ファーマシューティカル インダストリーズ リミティド | レストレスレッグス症候群の治療のためのラサギリンの使用 |
| CN104367565A (zh) * | 2014-11-21 | 2015-02-25 | 哈尔滨圣吉药业股份有限公司 | 一种盐酸普拉克索缓释微丸 |
| CN105147627B (zh) * | 2015-08-19 | 2019-04-12 | 天津红日药业股份有限公司 | 一种含有盐酸普拉克索的药物组合物及其制备方法 |
| EP3668501A4 (en) * | 2017-08-17 | 2021-03-17 | Zi-Qiang Gu | MONOAMINE PAMOATE SALTS ANTI-PARKINSON AGENTS, THEIR PREPARATION AND USE |
| KR20210106477A (ko) * | 2018-12-19 | 2021-08-30 | 갈렉토 바이오테크 에이비 | 5-브로모피리딘-3-일 3-데옥시-3-[4-(3,4,5-트리플루오로페닐)-1h-1,2,3-트리아졸-1-일]-1-티오-알파-d-갈락토피라노사이드의 비정질 형태 |
| JP2023504876A (ja) * | 2019-12-06 | 2023-02-07 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | 薬物組成物、キット及びその応用 |
| WO2023112024A1 (en) * | 2021-12-14 | 2023-06-22 | Pharma Two B Ltd. | Method of treating parkinson's disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL215263B1 (pl) * | 2002-02-25 | 2013-11-29 | Elan Pharm Inc | Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku |
| WO2005070428A1 (en) * | 2004-01-22 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist |
| AU2005215136A1 (en) * | 2004-02-20 | 2005-09-01 | Novartis Ag | DPP-IV inhibitors for treating neurodegeneration and cognitive disorders |
| WO2006014973A2 (en) * | 2004-07-26 | 2006-02-09 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical dosage forms including rasagiline |
| JP5769923B2 (ja) | 2006-04-03 | 2015-08-26 | テバ ファーマシューティカル インダストリーズ リミティド | レストレスレッグス症候群の治療のためのラサギリンの使用 |
| JP2010525018A (ja) * | 2007-04-24 | 2010-07-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物 |
| CN102105169B (zh) * | 2008-06-06 | 2014-09-10 | 图必制药公司 | 用于治疗帕金森病的药物组合物 |
| KR20110071064A (ko) * | 2008-08-19 | 2011-06-28 | 크놉 뉴로사이언시스 인코포레이티드 | (ｒ)-프라미펙솔을 사용하는 조성물 및 방법 |
| JP6045347B2 (ja) * | 2010-02-03 | 2016-12-14 | ファーマ ツー ビー リミテッド | ラサギリンの持続放出性製剤およびその使用 |
-
2013
- 2013-01-10 LT LTEP13736198.6T patent/LT2802319T/lt unknown
- 2013-01-10 EP EP13736198.6A patent/EP2802319B1/en active Active
- 2013-01-10 CN CN201380014052.8A patent/CN104168896B/zh active Active
- 2013-01-10 DK DK13736198.6T patent/DK2802319T3/da active
- 2013-01-10 WO PCT/IL2013/050025 patent/WO2013105092A1/en not_active Ceased
- 2013-01-10 HU HUE13736198A patent/HUE038029T2/hu unknown
- 2013-01-10 PT PT137361986T patent/PT2802319T/pt unknown
- 2013-01-10 PL PL13736198T patent/PL2802319T3/pl unknown
- 2013-01-10 NO NO13736198A patent/NO2802319T3/no unknown
- 2013-01-10 MX MX2014008537A patent/MX360409B/es active IP Right Grant
- 2013-01-10 KR KR1020147022416A patent/KR102276896B1/ko active Active
- 2013-01-10 IN IN1568MUN2014 patent/IN2014MN01568A/en unknown
- 2013-01-10 RS RS20180050A patent/RS56742B1/sr unknown
- 2013-01-10 RU RU2014132940A patent/RU2642962C9/ru active
- 2013-01-10 KR KR1020207002459A patent/KR20200013791A/ko not_active Ceased
- 2013-01-10 ES ES13736198.6T patent/ES2655676T3/es active Active
- 2013-01-10 CA CA2860952A patent/CA2860952C/en active Active
- 2013-01-10 AU AU2013208653A patent/AU2013208653B2/en active Active
- 2013-01-10 US US14/372,067 patent/US20150079187A1/en not_active Abandoned
- 2013-01-10 JP JP2014551726A patent/JP6243351B2/ja active Active
- 2013-09-30 NO NO13840443A patent/NO2901008T3/no unknown
-
2014
- 2014-07-09 IL IL233572A patent/IL233572B/en active IP Right Grant
-
2018
- 2018-01-17 CY CY20181100061T patent/CY1119793T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Moszczynska et al. | Molecular, behavioral, and physiological consequences of methamphetamine neurotoxicity: implications for treatment | |
| DK2802319T3 (da) | Fastdosiskombinationsterapi for parkinsons sygdom | |
| JP2013155188A5 (https=) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| IL232764A (en) | Fluoromethyl6,5 - Dihydro - 4 H - [3,1] Oxazines, Pharmaceuticals Containing Them and Their Use in the Preparation of Medicines to Treat Alzheimer's Disease | |
| PH12014501997A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| WO2011088120A8 (en) | Antibody formulation and therapeutic regimens | |
| WO2013170068A3 (en) | Nuclear transport modulators and uses thereof | |
| MX2010005631A (es) | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. | |
| JP2013522184A5 (https=) | ||
| SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| IL223783B (en) | Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine | |
| IL232325A0 (en) | 18-methyl-7,6-methylene-3-oxo-17-paragan-4-en-21, 17b-carbolactones, pharmaceutical preparations containing these compounds and their use for the treatment of endometrial disease | |
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| HK1223304A1 (zh) | 包含二甲双胍和二氢槲皮素的药物组合及其用於治疗癌症的用途 | |
| WO2013188210A3 (en) | Treatment of side effects associated with parkinson's disease treatments | |
| EA201501164A1 (ru) | Твердая фармацевтическая лекарственная форма | |
| TN2016000121A1 (en) | Cyclic thienouracil-carboxamides and use thereof | |
| UA118474C2 (uk) | (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
| HK1225972A1 (zh) | 利用拉喹莫德来延缓亨廷顿氏病的进展 | |
| PH12015501538A1 (en) | Topical ocular analgesic agents | |
| WO2013111013A3 (en) | Methods for treating alzheimer's disease by administering certain synthetic compounds | |
| UA112981C2 (uk) | Варіант людського gdnf | |
| WO2013038200A3 (en) | Neurodevelopmental disorders |